Patients must have recovered to =< grade following a significant adverse event or toxicity attributed to previous anti-cancer treatment except neurotoxicity which must be =< grade CNS toxicity =< grade Resolution of toxicity from prior anti-cancer therapy, to NCI CTCAE v. Grade or , except for alopecia. Subjects may be enrolled if their toxicity is determined to be irreversible and will not put them at undue risk from study treatment, based on the Investigator's assessment. CNS toxicity =< grade Grade > gastrointestinal toxicity that cannot be managed with supportive care measures. Subject has any Grade ? persistent non-hematological toxicity related to allotransplant Presence of ? CTCAE Grade toxicity due to prior cancer therapy. Failure to recover from any immune-related toxicity from prior cancer therapy to ? Grade . Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ? Grade . CTCAE Version , Grade non-hematological toxicity (except for alopecia, nausea, vomiting). Subjects with known persistent (> weeks) >= grade toxicity from prior cancer therapy Subjects with known >= grade hematological toxicity with the last chemotherapy regimen Grade or higher toxicity effects from previous treatment with immunotherapy Patients with history of any grade toxicity during previous anti PD- treatment or history of grade or higher pneumonitis Must have discontinued radiotherapy at least days with resolution of any toxicity to Grade or better prior to the start of treatment. Patients with a prior history of pulmonary toxicity due to medications (Ex: history of carmustine [BCNU] toxicity). Previous exposure to gemcitabine will only be allowed if there is no residual toxicity from previous treatments. Toxicity must be graded as or prior to study Neuropathy as residual toxicity after prior antitumor therapy Grade > Patients who experienced grade or above skin toxicity from prior EGFR inhibiting therapy Patients who have experienced grade or above toxicity from prior anti-PD therapy Residual or ongoing ? Grade toxicity from chemotherapy Recovered from any prior treatment related toxicity to at least Grade with exception of Grade alopecia or other Grade toxicity with prior approval of the Medical Monitor Subjects with history of grade toxicity or use of infliximab with prior immunotherapy Presence of grade or greater toxicity from the previous treatment. Ongoing clinically significant toxicity (Grade or greater) associated with prior treatment (including radiotherapy or surgery). Unresolved toxicity from previous anticancer treatments, including investigational products (subjects must have recovered all unacceptable toxicity to ? Grade Common Terminology Criteria for Adverse Events [CTCAE] toxicity). This does not extend to symptoms or findings that are attributable to the underlying disease Hydroxyurea may be used to control leukocytosis, provided that it is without grade > toxicity, and can be taken until start of therapy Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade except for grade alopecia or neuropathy. To be eligible for study treatment, toxicity from prior treatment must recover to Grade ? , except for alopecia To be eligible for study treatment, radiation therapy-related toxicity must recover to Grade ? prior to administration of the first dose of ARQ . Has experienced grade toxicity on treatment with prior radiation PRIOR TO LYMPHODEPLETION: For grade neutropenia, ? grade febrile neutropenia, or grade thrombocytopenia, hold bendamustine until toxicity resolve to ? grade Toxicity from a previous anti-tumor treatment that does not return to Grade or (except for alopecia); To be eligible for study treatment, toxicity from prior treatment must recover to Grade ? , except for alopecia Patients who have residual toxicity(-ities) from previous anti-cancer treatment(s) that is/are clinically significant or > grade are excluded; those whose toxicity(-ities) improved to grade or better will be eligible Any clinically significant toxicity from prior therapy must have improved to grade or grade Skin toxicity no greater than grade Prior grade toxicity attributed to cytarabine Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade , except for grade hematologic toxicity Recovered from toxicity of previous chemotherapy (excludes grade neurotoxicity and hematological toxicity) Any previous history of >= grade toxicity to dasatinib If the patient has residual toxicity from prior treatment, toxicity must be =< grade Severe major organ toxicity: specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade or less; a grade hearing deficit is acceptable Subjects experiencing toxicity with ibrutinib Subjects experiencing toxicity with ibrutinib Severe immune-related toxicity related to checkpoint inhibitors defined as any Grade toxicity or Grade toxicity Severe immune-related toxicity related to checkpoint inhibitors defined as any Grade toxicity or Grade toxicity Presence of any CTCAE grade or greater toxicity Patients will be ineligible if they have a baseline neurologic toxicity of grade or greater Any Grade ? persistent non-hematological toxicity related to allotransplant Resolution of all chemotherapy related grade III-IV toxicity Skin toxicity =< grade Grade or greater toxicity from prior therapy Patients who have a CNS toxicity > grade are not eligible Subjects who experienced grade or toxicity regardless of causality to the cell infusion must have had a reduction to a grade or less or returned to baseline levels Omission of cytotoxic chemotherapy or other systemic therapy of the malignancy for >= weeks prior to entry into the trial; patients must be >= weeks since major surgery, radiotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to =< Common Toxicity Criteria (CTC) grade , exclusive of grade alopecia, fatigue, lymphopenia, CD+ circulating T cells, white blood count (WBC) or bilirubin History of significant intolerance to capecitabine or fluorouracil (FU) (ie. grade toxicity related to one of these agents; grade - toxicity related to other concurrently administered agents is not an exclusion) Grade colitis, hepatitis, pneumonitis uveitis, myocarditis, myositis, CNS toxicity or autoimmune related neuromuscular toxicity such as myasthenia gravis associated with the administration of an immune checkpoint inhibitor Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling. No neurosensory or neuromotor toxicity >= grade at the time of registration Grade or toxicity related to prior VEGFR TKI that did not resolve to grade Uncontrolled grade or greater toxicity except alopecia Presence of grade or greater toxicity from the previous treatment known and persistent (> weeks) >/= grade toxicity or fatigue from prior cancer treatment. Toxicity of ? Grade from prior anticancer therapy Grade ? toxicity (other than alopecia). Patients with > grade neurologic toxicity at the time of treatment Patients will be ineligible if they have a baseline neurologic toxicity of grade or greater Any systemic therapy associated toxicity should be grade or less Recovered from toxicity of previous chemotherapy (excludes grade neurotoxicity and hematological toxicity) Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade >/=). Alopecia is permitted Any previous history of >= grade toxicity to Dasatinib Any history of previous >= grade toxicity attributable to erlotinib (except dermatological toxicity) History of persistent Grade or higher hematological toxicity according to National Cancer Institute-Common Toxicity Criteria Version . Patients must not have a history of grade >= neurological toxicity with previous treatment, or persistent grade >= peripheral neuropathy; drowsiness and lethargy were exempted from this criteria unless previously persistent for more than one week PRIOR TO MOBILIZATION THERAPY: Resolution of grade III-IV toxicity associated with pre-transplant therapy PRIOR TO HIGH-DOSE CHEMOTHERAPY: Patients without evidence of ongoing grade III-IV toxicity related to mobilization therapy Discontinuation of ibrutinib treatment at an earlier time due to toxicity Participant with ? Grade (CTCAE v .-JCOG) persistent symptoms and objective findings due to the toxicity attributable to prior treatment with antitumor effect (except alopecia). Treatment related residual toxicity > grade Unresolved toxicity >= Common Terminology Criteria for Adverse Events (CTCAE) grade from previous anti-cancer therapy except alopecia or long-term radiation toxicity (radiation related toxicity months or greater after radiation exposure) Patients with chronic grade or toxicity may be eligible at the discretion of the principal investigator if the condition has been stable, and not worsening, for at least days; patients with ongoing alopecia of any grade will be eligible Have unresolved toxicity from previous treatment or previous investigational agents; excluding alopecia; clinical judgment by the investigator is allowed to determine if grade fatigue at screening is residual toxicity from prior treatment or is a symptom of the patients general condition or disease; the investigator and medical monitor will discuss the eligibility of patients with baseline toxicity Prior clinically significant grade - non-hematological toxicity to high dose Ara-C or grade ? of neurological toxicity. Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; if the patient has residual toxicity from prior treatment, toxicity must be =< grade (or =< grade for peripheral neuropathy and/or alopecia) Residual toxicity of > grade from prior therapy Must not be experiencing a Grade or toxicity from previous anti-cancer treatment Patient has received other chemotherapeutic, hormonal, or investigational anti cancer agents that are outside of the timeframe described above and thus would be allowed in the study, but has toxicity that is unresolved (i.e., toxicity has resolved to Grade ? or is deemed irreversible) Reduction of any acute toxicity from radiation treatment to grade Have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment, with the exception of alopecia and ?Grade peripheral neuropathy according to the NCI CTCAE v.. Clinical judgment by the investigator is allowed to determine if Grade fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient's general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline toxicity. No grade or gastrointestinal (GI) toxicity at time of initial screening PHASE I: Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =< grade Major organ toxicity including cardiac, pulmonary, gastrointestinal and neurologic toxicity more than grade Resolution of treatment-related toxicity to < grade ; alopecia and cutaneous toxicity are allowed < grade grade to nonhematologic toxicity that does not resolve with adequate intervention any grade or greater toxicity that is unacceptable to the patient Failure to recover from Grade or toxicity from previous treatment Failure to recover from Grade or toxicity from previous treatment (unrelated to malignant bone marrow involvement)